Protalix BioTherapeutics
PLX
25 hedge funds and large institutions have $18.4M invested in Protalix BioTherapeutics in 2020 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 6 closing their positions.
608% more call options, than puts
Call options by funds: $658K | Put options by funds: $93K
80% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 5
1.54% less ownership
Funds ownership: 16.22% → 14.68% (-1.5%)
7% less capital invested
Capital invested by funds: $19.8M → $18.4M (-$1.37M)
11% less funds holding
Funds holding: 28 → 25 (-3)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$173K |
| 2 |
Squarepoint
New York
|
+$162K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$138K |
| 4 |
PF
Phoenix Financial
Givatayim,
Israel
|
+$57.9K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$57.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$1.35M |
| 2 |
Jane Street
New York
|
-$467K |
| 3 |
Walleye Capital
New York
|
-$222K |
| 4 |
Renaissance Technologies
New York
|
-$145K |
| 5 |
Walleye Trading
New York
|
-$140K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Citadel Advisors
Miami,
Florida
| – | -$87K | -24,047 | Closed |
|
|
CS
27
Credit Suisse
Zurich,
Switzerland
| – | -$38K | -10,000 | Closed |
|
|
SPIA
28
Steward Partners Investment Advisory
New York
| – | -$1K | -200 | Closed |
|
29
Morgan Stanley
New York
| – | +$181 | +50 | New |
|
30
Osaic Holdings
Scottsdale,
Arizona
| – | +$362 | +100 | New |
|
PLX Hedge Fund Activity: Q3 2020 in Review
25 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q3 2020, worth a combined $18.4M — down 6.9% from $19.8M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of PLX and 3 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 9 added.
The largest buyer was Kennedy Capital Management, adding an estimated $173K. The largest seller was UBS O'Connor, cutting an estimated $1.35M.
- 25 institutional investors held Protalix BioTherapeutics (PLX) as of Q3 2020, down from 28 in Q2 2020.
- Funds reported $18.4M of Protalix BioTherapeutics stock for Q3 2020, down 6.9% quarter-over-quarter.
- 3 funds opened new Protalix BioTherapeutics positions in Q3 2020 and 6 closed out, a net change of -3 holders.
- The largest Protalix BioTherapeutics buyer in Q3 2020 was Kennedy Capital Management, an estimated $173K added.
- The largest Protalix BioTherapeutics seller in Q3 2020 was UBS O'Connor, an estimated $1.35M sold.
Based on aggregated 13F filings for Q3 2020.